David M. Nathan, MD; Michael Berkwits, MSCE, Deputy Editor
Potential Financial Conflicts of Interest: Honoraria: D.M. Nathan (GlaxoSmithKline).
Requests for Single Reprints: David M. Nathan, MD, Massachusetts General Hospital Diabetes Unit, 50 Staniford Street, 3rd Floor, S503, Boston, MA 02114; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Nathan: Massachusetts General Hospital Diabetes Unit, 50 Staniford Street, 3rd Floor, S503, Boston, MA 02114.
Dr. Berkwits: American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106.
Learn more about subscription options.
Register Now for a free account.
Nathan DM, Berkwits M. Trials That Matter: Rosiglitazone, Ramipril, and the Prevention of Type 2 Diabetes. Ann Intern Med. 2007;146:461-463. doi: 10.7326/0003-4819-146-6-200703200-00015
Download citation file:
Published: Ann Intern Med. 2007;146(6):461-463.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Hypertension.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only